Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure

Loek A W de Jong, Fortuné M K Elekonawo, Philip R de Reuver, Andre J A Bremers, Johannes H W de Wilt, Frank G A Jansman, Rob Ter Heine, Nielka P van Erp

    Onderzoeksoutput: Review articlepeer review

    16 Citaten (Scopus)
    74 Downloads (Pure)


    Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become the standard of care in the treatment of patients with peritoneal carcinomatosis of colorectal origin. The use of oxaliplatin for HIPEC has gained popularity. Although the HIPEC procedure is adopted throughout the world, major differences exist between treatment protocols regarding the carrier solution, perfusate volume, use of an open or closed technique, duration of the perfusion and application of additional flushing. These differences can influence the pharmacokinetics and pharmacodynamics of oxaliplatin and might thereby have an impact on the efficacy and/or safety of the treatment. Clinicians should be aware of the clinical importance of oxaliplatin pharmacology when performing HIPEC surgery. This review adds new insights into the complex field of the pharmacology of HIPEC and highlights an important worldwide problem: the lack of standardization of the HIPEC procedure.

    Originele taal-2English
    Pagina's (van-tot)47-58
    Aantal pagina's12
    TijdschriftBritish Journal of Clinical Pharmacology
    Nummer van het tijdschrift1
    Vroegere onlinedatum25-sep.-2018
    StatusPublished - jan.-2019

    Citeer dit